Dedicated to Developing Novel Medicines for CNS Diseases

About Us

Committed to Advancing a New Generation of Oral Antidepressants

AV-101, an NMDA receptor glycine-binding (GlyB) site antagonist, is a new generation oral antidepressant drug candidate in Phase 2 development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard FDA-approved antidepressants, which consist primarily of commonly prescribed selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Inspired by breakthrough clinical studies involving intravenous administration of a low dose of the FDA-approved anesthetic ketamine, orally-available AV-101's mechanism of action, and that of ketamine, is fundamentally differentiated from all FDA-approved antidepressants and atypical antipsychotics (such as aripiprazole) often administered with them, adjunctively.

VistaGen Therapeutics, Inc. Pipeline
What Makes AV-101 Different?

Going Above and Beyond Current Treatment Options

Focused on providing novel solutions for millions of depression patients with inadequate response to standard FDA-approved antidepressants.

Learn More About Ketamine and AV-101

Backed by an Experienced Leadership Team

Our highly experienced Management Team, Board of Directors, and CNS Clinical and Regulatory Advisory Board have a proven track record of developing innovative medicines to treat a wide range of CNS diseases and disorders.

Meet Our Team

Stock Information

View Detailed Stock Info
NASDAQ: VTGN Symbol
Price
Change
Volume
Day Range
52 Week Range

Corporate Presentation

For Investors

Email Updates

Be the first to receive news, events & updates Sign Up